Trading Statement

18 April 2007

                                  Lawrence plc
                     Update on the year ended 31 March 2007

The Directors are today providing an update on the Company's performance for the
twelve   months  to  31  March  2007  and  anticipate  that  revenues  will   be
approximately  £18.4  million.   This includes  a  contribution  from  the  Agil
division  that was sold in November 2006.  Following the sale of Agil,  Lawrence
is almost exclusively focussed on its Eco Animal Health business.

Eco delivered another encouraging performance during the year, with record sales
and  profit  before  amortisation. Sales of Aivlosin, Eco's  patented  macrolide
antibiotic,  increased by almost 33 per cent over last year with  sales  outside
Europe  and the US almost 25 per cent ahead and Europe close to 70 per cent  up,
thus  firmly demonstrating the exceptional qualities of this medication.   While
this  is  an  impressive performance, the Directors had expected that  sales  of
Aivlosin  would  be  even higher, particularly in Europe where  Schering  Plough
Animal  Health,  one  of  the world leaders in the animal  health  industry,  is
contracted  to  distribute Aivlosin in the majority of  the  27  European  Union
countries.

In  the  EU,  Aivlosin has approval for swine and is sold as a high performance,
high  dose,  premium  drug.  Eco  has  been investigating  more  cost  effective
treatment regimens for Europe, similar to those successfully established in  the
rest  of  the world, and plans to discuss the recent trial data informally  with
the  EMEA  assessors this quarter with a view to submitting an  application  for
approval for lower dose usage.

Schering  Plough is establishing Aivlosin although it has not yet  launched  all
presentations across its entire territory, as some EU countries have  been  slow
to agree local labelling requirements.

We  are  working  closely with Schering Plough, through  a  programme  of  joint
marketing trials, to accelerate the penetration in these important markets,  but
there will continue to be some impact on Aivlosin sales in Europe in the current
financial year.  Nevertheless, we expect significant progress to be made in  the
EU  and  that should further accelerate when the expected lower dosage marketing
approvals are obtained.

Although  the  Group profit before tax will be boosted by the  proceeds  of  the
disposal  of  the Agil division, as a consequence of the lower than  anticipated
sales  of Aivlosin, the profit before tax on continuing operations for the  year
ended 31 March 2007 will be behind market expectations.

Eco's  drug registration programme continues apace and we are expecting  further
important  approvals in Europe, Australia, India and Japan during the course  of
the current year.

In  November  we  announced  that  our  collaborative  research  programme  with
Cambridge  University had indicated that Aivlosin may be suitable  for  treating
certain  additional  diseases  in  pigs and  poultry.   Trials  involving  these
exciting  discoveries have commenced and the first results should  be  available
soon  and this may lead to more trial work to establish treatments for a  number
of important diseases.

The  underlying trend for the current year is strong and we expect solid  growth
in   profit   boosted  by  another  significant  increase  in  Aivlosin   sales.
Penetration  of the EU markets will be an area of particular focus  and  Eco  is
working closely alongside Schering Plough to achieve this.

                          -----------------------------

Enquires
Lawrence        plc                                         Peter       Lawrence
020 8336 6190

Charles Stanley Securities               Philip Davies                       020
7149 6224

Nomura  Code  Securities Ltd           Chris  Collins                        020
7776 1200


Lawrence plc is a leader in the development, manufacture and distribution of
principally specialist chemical and pharmaceutical products for the animal
health and farming markets worldwide. We achieve our financial goals through the
careful and responsible application of science to generate value for our
shareholders.

www.lawrenceplc.com